Advertisement

Hypertension

Chapter
  • 263 Downloads
Part of the Treatment in Clinical Medicine book series (TC MEDICINE)

Abstract

Our attitude to hypertension has changed dramatically in the past 30 years. This has been reflected in terms of investigation, in terms of medical and surgical management and in the development of hypertension as a speciality. While hypertension developed initially as a hospital-orientated problem, the trend now is towards “shared care” or general practitioner management. The search for aetiology of primary (also known as idiopathic and misleadingly as “essential”) hypertension previously dominated the assessment of patients. Hypertensive patients — young or old, male or female — underwent a battery of investigations such as intravenous pyelography, radio-isotope renography and at times aortography. Complex biochemical investigations were also included. Investigation is now more selective. It is extremely complex when necessary, but overall has become simpler. The need for treatment can be based on general criteria:
  1. Stage 1:

    Raised blood pressure. No organ involvement. Consider therapy.

     
  2. Stage 2:

    Raised blood pressure. Organ involvement (e.g. LV hypertrophy). Treatment indicated.

     
  3. Stage 3:

    Raised blood pressure. Organ failure or damage (e.g. cardiomegaly, blood urea raised). Treatment mandatory.

     

Keywords

Blood Pressure Cardiac Output Blood Pressure Control Diastolic Pressure Peripheral Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson RJ, Hart GR, Grumpier CP, Reed WG, Mathews CA, (1981) Oral Clonidine loading in hypertensive urgencies. JAMA 246: 848–850PubMedCrossRefGoogle Scholar
  2. Aoki K, Kondo S, Mochizuke A, Yoshida T, Kato S, Takikawa K (1978) Antihypertensive effect of cardiovascular Ca++ antagonists in hypertensive patients in the absence and presence of beta adrenergic blockade. Am Heart J 96: 218–226PubMedCrossRefGoogle Scholar
  3. Atkinson AB, Brown JJ, Lever AF, Robertson JIS (1980) Combined treatment of severe intractable hypertension with captopril and diuretic. Lancet II: 105–107CrossRefGoogle Scholar
  4. Bayley S, Dobbs PJ, Robinsin BF (1982) Nifedipine in the treatment of hypertension: report of a double blind controlled trial. Br J Clin Pharmacol 14: 509–512PubMedGoogle Scholar
  5. Beer N, Gallegos I, Cohen A, Klein N, Sonnenblick E, Frishman W (1981) Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension. Chest 79: 571–574PubMedCrossRefGoogle Scholar
  6. Beilin LH, Juel-Jensen BE (1972) Alpha and beta adrenergic blockade in hypertension. Lancet I: 979–982CrossRefGoogle Scholar
  7. Bertel O, Conen D, Radv EW, Muller J, Lang C, Dubach UC (1983) Nifedipine in hypertension emergencies. Br Med J 286: 19–21CrossRefGoogle Scholar
  8. Buhler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR (1972) Propranolol inhibition of rennin secretion. N Engl J Med 287: 1209–1214PubMedCrossRefGoogle Scholar
  9. Buhler FR, Hulthen UL, Kiowski W, Muller FB, Bolli P (1982) The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol 4 [Suppl]: 350–357CrossRefGoogle Scholar
  10. Dollery CT, Lewis PJ, Myers MG (1973) Central hypotensive effect of propranolol in the rabbit. Br J Pharmacol 48: 343Google Scholar
  11. Editorial (1983) Lancet II: 22–24Google Scholar
  12. European Working Party on high blood pressure in the elderly (1985) Mortality and morbidity results from the Working Party on high blood pressure in the elderly trial. Lancet II: 1349-1354Google Scholar
  13. Gallery EDM, Saunders DM, Munyor SM, Gyopy AZ (1979) Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy. Br Med J I: 1591-1594CrossRefGoogle Scholar
  14. Goldstein GB, Lam KC, Mistilis SP (1973) Drug induced active chronic hepatitis. Am J Digest Dis 18: 177–184PubMedCrossRefGoogle Scholar
  15. Gould BA, Horning RS, Mann S, Balasubramanian V, Raftery EB (1982) Slow channel inhibitors verapamil and nifedipine in the management of hypertension. J Cardiovasc Pharmacol 4 [Suppl]: 369–373CrossRefGoogle Scholar
  16. Guidelines for the treatment of mild hypertension: memorandum from a W.H.O./I.S.H. meeting (1983) Lancet I: 457–458Google Scholar
  17. Hansson L, Zweifler AJ, Julius S (1974) Propranolol therapy in essential hypertension. Observations on predictability of therapeutic response. Int J Clin Pharmacol 10: 79–86PubMedGoogle Scholar
  18. Hoffman BB, Lefkowitz RJ (1980) Alpha-adrenergic receptor subtypes. N Engl J Med 302: 1390-1397PubMedCrossRefGoogle Scholar
  19. Hollifield JW, Sherman K, Vander Zwagg R, Shand DG (1976) Proposed mechanisms of propranolol’s antihypertensive effect in essential hypertension. N Engl Med 295: 68–73CrossRefGoogle Scholar
  20. Hutchison S, Campbell LM (1983) Beta-blockers and the elderly. J Clin Hosp Pharm 8: 191–194PubMedGoogle Scholar
  21. Hypertension Detection and Follow-up. Program Co-operative Group (1979) Five year findings of the hypertension detection and follow-up program. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242: 2562–2571CrossRefGoogle Scholar
  22. Kannel WB (1977) An overview of the risk factors for cardiovascular disease In: Genest S, Koiw E, Kuchel OED (eds) Hypertension, physiopathology and treatment. McGraw Hill, New YorkGoogle Scholar
  23. Kannel WB, Gordon T (1978) Evaluation of the cardiovascular risk in the elderly: The Framingham Study. Bull N Y Acad Med 54: 573–591PubMedGoogle Scholar
  24. Kannel WB, Gordon T, Schwartz MG (1971) Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham Study. Am J Cardiol 27: 335–346PubMedCrossRefGoogle Scholar
  25. Koch-Weser J (1973) Correlation of pathophysiology and pharmacotherapy in primary hypertension. Am J Cardiol 32: 499–510CrossRefGoogle Scholar
  26. Langer SZ (1976) The role of alpha and beta presynaptic receptors in the regulation of noradrenaline release elicited by nerve stimulation. Clin Sci Sl (Suppl 3): 421–426Google Scholar
  27. Ledingham JGG, Rajagopalan B (1979) Cerebral complications in the treatment of accelerated hypertension. Q J Med 48: 25–41PubMedGoogle Scholar
  28. Lewis PG, Haeusler G (1975) Reduction in sympathetic nervous activity as a mechanism for hypotensive effect of propranolol. Nature 256: 440PubMedCrossRefGoogle Scholar
  29. Lorimer AR, Barbour M, Hillis WS, Lawrie TDV, Stoker JB, Sreeharan N, Leanage RV, Linden RJ (1980) Long term comparison of metoprolol and methyldopa in the treatment of hypertension. Clin Cardio 3: 36–39Google Scholar
  30. Lowe GDO (1983) Vasodilators: minoxidil and drugs used in peripheral vascular and cerebral disorders. Br Med J 286: 1262–1264CrossRefGoogle Scholar
  31. Lund-Johansen P (1970) Haemodynamic changes in long term diuretic therapy of essential hypertension. Acta Med Scand 187: 509–518PubMedCrossRefGoogle Scholar
  32. Lund-Johansen P (1972) Haemodynamic changes in long term alpha methyldopa therapy of essential hypertension. Acta Med Scand 192: 221–226PubMedCrossRefGoogle Scholar
  33. Lund-Johansen P (1979) Haemodynamic consequences of long term beta-blocker therapy: a 5 year follow-up study of atenolol. J Cardiovasc Pharmacol 1: 487–495CrossRefGoogle Scholar
  34. McAreavey D, Ramsey LE, Latham L, Lorimer AR, McLaren D, Reid JL, Robertson JIS, Robertson MP, Weire RJ (1983) The “third drug” trial. J Hypertension 1 (Suppl 2): 116–120Google Scholar
  35. MacKay A, Isles C, Henderson I, Fife R, Kennedy AC (1981) Minoxidil in the management of refractory hypertension. Q J Med 198: 175–190Google Scholar
  36. Management Committee (1980) The Australian therapeutic trial in mild hypertension. Lancet I: 1261–1267Google Scholar
  37. Medical Research Council Working Party (1985) MRC trial of treatment of Mild Hypertension: principal results. Br Med J 291: 97–104CrossRefGoogle Scholar
  38. Morgan T, Adam W, Gillies A, Wilson M, Morgan G, Carney S (1978) Hypertension treated by salt restriction. Lancet I: 227–230CrossRefGoogle Scholar
  39. Morton JJ, Tree M, Casals-Stenzel J (1982) Effect of infused Captopril on blood pressure and the renin angiotensin aldosterone system in normal dogs subjected to varying sodium balance. Am J Cardiol 49: 1395–1400PubMedCrossRefGoogle Scholar
  40. Motulsky HJ, Insel PA, (1982) Adrenergic receptors in man. N Engl J Med 307: 18–29PubMedCrossRefGoogle Scholar
  41. Motulsky HJ, Snavely MD, Hughes RJ, Insel PA (1983) Interaction of verapamil and other calcium channel blockers with 1 2 adrenergic receptors. Circ Res 52: 226–231PubMedGoogle Scholar
  42. MRC Working Party on Mild to Moderate Hypertension (1981) Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet II: 539–543Google Scholar
  43. Murphy MB, Scriven AJI, Dollery CT (1983) Role of nifedipine in treatment of hypertension. Br Med J 287: 257–259CrossRefGoogle Scholar
  44. Olivari MT, Bartorelli C, Polese A, Fiorentini C, Moruzzi P, Guazzi MD (1979) Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation 59: 1056–1062PubMedGoogle Scholar
  45. O’Malley K, O’Brien E (1980) Management of hypertension in the elderly. N Engl J Med 302: 1397–1401PubMedCrossRefGoogle Scholar
  46. Parfrey PS, Markandu ND, Roulston JE, Jones BE, Jones JC, McGregor GA (1981) Relation between arterial pressure, dietary sodium intake and renin system in essential hypertension. Br Med J 283: 94–97CrossRefGoogle Scholar
  47. Personal Paper (1977) Trials and tribulations of a symptom-free hypertensive physician receiving the best of care. Lancet II: 291–292Google Scholar
  48. Prichard BNC, Gillam PMS (1969) Treatment of hypertension with propranolol. Br Med J I: 7–16CrossRefGoogle Scholar
  49. Redman CWG, Beilin LJ, Bonnar J, Dunsted MK (1976) Foetal outcome in trial of antihypertensive treatment in pregnancy. Lancet II: 753–756CrossRefGoogle Scholar
  50. Redman CWG, Beilin LJ, Bonnar J (1977) Treatment of hypertension in pregnancy with methyldopa — blood pressure control and side effects Br J Obstet Gynaecol 84: 419–426PubMedCrossRefGoogle Scholar
  51. Robertson JIS (1982) Labetalol: The nineteen eighties. Br J Clin Pharmacol 13 [Suppl 1]: 137–141Google Scholar
  52. Robinson BF, Dobbs RJ, Bayley S (1983) Response of forearm resistance vessels to verapamil and sodium nitroprusside in normotensive and hypertensive men: evidence for a functional abnormality of vascular smooth muscle in primary hypertension. Clin Sci 63: 33–42Google Scholar
  53. Rose G (1981) Strategy of prevention: lessons from cardiovascular disease. Br Med J 282: 1847-1851CrossRefGoogle Scholar
  54. Rubin PC, Reid JL (1983) Alpha-blockers and converting enzyme inhibitors. Br Med J 286:1192-1195CrossRefGoogle Scholar
  55. Rubin PC, Clark DM, Sumner DJ, Low RA, Butters L, Reynolds B, Steedman D, Reid JL (1983) Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet I: 431–436Google Scholar
  56. Sandstrom B (1978) Antihypertensive treatment with the adrenergic beta receptor blocker metoprolol during pregnancy. Gynecol Invest 9: 195–204PubMedCrossRefGoogle Scholar
  57. Taverner D, Bing RF, Heagerty A, Russell GI, Pohl JEF, Swales JD, Thurston H (1983) Improvement of renal function during long term treatment of severe hypertension with minoxidil. Q J Med 206: 280–287Google Scholar
  58. Tung LH, Rand MJ, Majewski H (1981) Adrenaline-induced hypertension in rats. Clin Sci 61 (Suppl 7): 191–193Google Scholar
  59. Veterans’ Administration Co-operative Study Group (1967) Effects of treatment of morbidity in hypertension. JAMA 202: 1028–1034CrossRefGoogle Scholar
  60. Veterans’ Administration Co-operative Study Group (1970) Effects of treatment of morbidity in hypertension. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 213: 1143–1152CrossRefGoogle Scholar
  61. Veterans’ Administration Co-operative Study Group on Antihypertensive Agents (1982) Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. JAMA 248: 1996–2003CrossRefGoogle Scholar
  62. Vidt DG, Bravo EL, Fouad FM (1982) Captopril. N Engl J Med 306: 214–219CrossRefGoogle Scholar
  63. Vilsvik JA, Schannin J (1976) Effect of atenolol on ventilatory function in asthma. Br Med J II: 453–455CrossRefGoogle Scholar
  64. Walker J, Greer I, Calder AA (1983) Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. Postgrad Med J 59 (Suppl 3): 168–170PubMedGoogle Scholar
  65. Watt GCM, Edwards C, Hart JT, Hart M, Walton P, Foy CW (1983) Dietary sodium restriction for mild hypertension in general practice. Br Med J 282: 432–436CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  1. 1.Royal InfirmaryGlasgowScotland, UK
  2. 2.Stobhill General HospitalGlasgowScotland, UK

Personalised recommendations